# Tirzepatide: Dual GIP/GLP-1 Research Digest — Mechanism, Efficacy, and Trial Data

> Tirzepatide is a dual GIP and GLP-1 receptor agonist studied across the SURPASS and SURMOUNT programs. Summaries of the clinical literature, sourced and cited.

## What the tirzepatide literature has demonstrated

Tirzepatide is a 39-amino-acid synthetic peptide that simultaneously activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) [1]. That dual mechanism — earned the term "twincretin" in the pharmacology literature — produces metabolic effects that exceed either receptor pathway activated in isolation.

The clinical record is extensive. The SURPASS program ran 10 phase 3 trials enrolling more than 13,000 adults with type 2 diabetes [2, 3, 4]. The SURMOUNT program extended the research into obesity, obstructive sleep apnea, heart failure, and liver disease [5, 6, 7, 8]. Across both programs, tirzepatide produced HbA1c reductions of 1.87–2.58% and body weight reductions of 16–22.5% at the 15 mg dose [2, 5].

## Tirzepatide as a Synthetic Peptide

Tirzepatide's 39-amino-acid backbone is based on the native GIP sequence, not GLP-1 [9]. A C20 fatty diacid moiety is attached via a linker at position 20, enabling reversible albumin binding. That modification extends plasma half-life from the minutes characteristic of native GIP to approximately 5.4 days in humans [9].

Molecular weight is approximately 4,813 Da. Subcutaneous bioavailability is ~80%, with Tmax between 8 and 72 hours post-injection [10]. It is classified as a synthetic incretin mimetic.

## Three findings that define the tirzepatide literature

**Body weight reduction in SURMOUNT-1.** At the 15 mg dose over 72 weeks in adults with obesity but without diabetes, tirzepatide produced a mean body weight reduction of 22.5% versus 2.4% for placebo (n=2,539) [5].

**Glycemic control across SURPASS.** In SURPASS-1, tirzepatide monotherapy reduced HbA1c by 1.87–2.07% at doses of 5–15 mg over 40 weeks versus +0.04% for placebo [2]. In SURPASS-4, 15 mg reduced HbA1c by 2.58% versus titrated insulin glargine [4].

**Cardiovascular safety confirmed.** SURPASS-CVOT enrolled 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Primary endpoint MACE occurred in 12.2% of the tirzepatide group versus 13.1% with dulaglutide — noninferiority to an active GLP-1 comparator demonstrated [19]. All-cause mortality was 16% lower with tirzepatide.

## What Is Tirzepatide?

Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at both GIP and GLP-1 receptors, studied in clinical trials for metabolic conditions including type 2 diabetes and obesity [1, 9]. It received FDA approval for type 2 diabetes in May 2022 and for chronic weight management in November 2023.

## What Is Tirzepatide Used For in Research?

Approved indications cover type 2 diabetes glycemic control and chronic weight management. Research programs have also studied tirzepatide in MASH (SYNERGY-NASH, 73.3% MASH resolution at 15 mg) [16]; heart failure with preserved ejection fraction (SUMMIT, 46% reduction in worsening HF events) [17]; and obstructive sleep apnea (SURMOUNT-OSA, 25–29 events/hour AHI reduction) [18].

## Is Tirzepatide a GLP-1 Agonist?

Yes — tirzepatide agonizes the GLP-1 receptor. But its primary structural identity is as a GIP analog, and its GIPR affinity is approximately 5-fold higher than its GLP-1R affinity [1].

## How Tirzepatide Aids in Weight Loss

By simultaneously activating GIP and GLP-1 receptors, tirzepatide reduces energy intake through appetite suppression, slows nutrient absorption via transient gastric emptying delay, and enhances fat oxidation through direct GIPR effects on adipose tissue [21, 22]. In SURMOUNT-1, participants on 15 mg lost a mean of 22.5% of body weight at 72 weeks [5].

## References

[1] Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
[2] Rosenstock J, et al. SURPASS-1. Lancet. 2021;398(10295):143-155.
[3] Frías JP, et al. SURPASS-2. N Engl J Med. 2021;385(6):503-515.
[4] Del Prato S, et al. SURPASS-4. Lancet. 2021;398(10313):1811-1824.
[5] Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387(3):205-216.
[6] Wadden TA, et al. SURMOUNT-3. Nature Medicine. 2023;29(11):2909-2918.
[7] Aronne LJ, et al. SURMOUNT-4. JAMA. 2024;331(1):38-48.
[8] Jastreboff AM, et al. SURMOUNT-5. N Engl J Med. 2025;393(1):26-36.
[9] Kaneko S. Tirzepatide structural review. touchREVIEWS in Endocrinology. 2022;18(1):10-17.
[10] Urva S, et al. Gastric emptying study. Diabetes Obes Metab. 2020;22:1886-1891.
[16] Loomba R, et al. SYNERGY-NASH. N Engl J Med. 2024;391(4):299-310.
[17] Bhatt DL, et al. SUMMIT. N Engl J Med. 2024;391(22):2057-2068.
[18] Malhotra A, et al. SURMOUNT-OSA. N Engl J Med. 2024;391(13):1193-1205.
[19] Nicholls SJ, et al. SURPASS-CVOT. N Engl J Med. 2025;393:2409-2420.
[20] Jastreboff AM, et al. SURMOUNT-1 3yr. N Engl J Med. 2025;392(13):1227-1239.
[21] Coskun T, et al. Adipocyte metabolism via GIP receptor. Cell Metabolism. 2024;36(7):1411-1429.
[22] Liu QK. GLP-1 and dual GIP/GLP-1 mechanisms. Frontiers in Endocrinology. 2024;15:1431292.

---

The tirzepatide clinical record — mechanism, trials, and pharmacokinetics — read from primary sources, cited numerically, and held by no clinic and no vendor.